Ark Investment Management Sells $11.2 Million in Twist Bioscience

Ark Investment Management, led by Cathie Wood, sold $11.2 million in shares of synthetic DNA manufacturer Twist Bioscience on June 30. This transaction involved more than 114,000 shares distributed across the Ark Innovation ETF and the Ark Genomic Revolution ETF. This sale followed an earlier divestment of more than 84,000 shares in the same month.

Wood utilized the freed capital to expand other positions, purchasing $3.9 million in Circle Internet Group, $3.6 million in SoFi Technologies, and $2.2 million in Recursion Pharmaceuticals. Despite the sales, Ark continues to hold substantial stakes in Twist Bioscience. As of July 15, the Ark Innovation ETF held over $211 million and the Ark Genomic Revolution ETF held more than $121 million in the company.

Twist Bioscience stock has risen more than 190% in 2026. However, the company continues to report net losses despite achieving 13 consecutive quarters of sequential revenue growth.